|
|
 |
| Primary Symbol & Exchange: |
| SGEN - Common Stock - NASDAQ |
|
|
| Industry: |
| Pharmaceutical |
|
|
|
|
|
|
|
Thomson Financial Business Description:
| The Group's principal activity is to develop and commercialize of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. Its antibody-based products that have been approved for the treatment of cancer include six engineered monoclonal antibodies (Rituxan(R), Herceptin(R), Campath(R), Avastin(R), Erbitux(R) and Vectibix(R)), two radionuclide-conjugated monoclonal antibodies (Zevalin(R), Bexxar(R) and an antibody-drug conjugate Mylotarg(R). It has three product candidates in ongoing clinical trials: dacetuzumab (SGN-40), lintuzumab (SGN-33) and SGN-70. Currently the Group has three preclinical programs, SGN-75, AGS-5 ADC and SGN-19A. The Group has collaborations with biotechnology and pharmaceutical companies, including Genentech Inc, Bayer Pharmaceuticals Corporation, CuraGen Corporation, Progenics Pharmaceuticals Inc, Daiichi Sankyo Co Ltd and MedImmune Inc, a subsidiary of AstraZeneca Inc. It operates in the United States. |
|
Alacra Alerts:
 
|
Receive alerts on the latest reports on Seattle Genetics, Inc.
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
|
|
